Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer

Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally ...

Report | 01-04-2019

Organisation structure National Health Care Institute

Publication | 26-03-2019

Amendment of the conditional inclusion of the medicine Fingolimod (Gilenya®) for the treatment of relapsing remitting multiple sclerosis (RRMS)

Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal  product ...

Report | 25-03-2019

Abemaciclib (Verzenios®) for the treatment of metastatic breast cancer

Zorginstituut Nederland has completed its assessment of abemaciclib (Verzenios®) for the treatment of metastatic breast cancer. ...

Report | 07-03-2019

Axicabtagene ciloleucel (Yescarta®) for the treatment of adult patients with recurring or refractory diffuse large-cell B-cell lymphoma (DLBCL) and primary mediastinal large-cell B-cell lymphoma (PMBCL)

Zorginstituut Nederland carried out an assessment of the medicinal product axicabtagene ciloleucel (axi-cel, Yescarta®) for the ...

Report | 07-03-2019

Tisagenlecleucel (Kymriah®) for the treatment of DLBCL

Zorginstituut Nederland has completed its assessment of tisagenlecleucel (Kymriah®) for the treatment of DLBCL. Due to its ...

Report | 07-03-2019

Rivaroxaban (Xarelto®) for the prevention of atherothrombotic complications in adult patients with coronary artery disease

Zorginstituut Nederland carried out an assessment of medicinal product rivaroxaban (Xarelto®). The manufacturer requested to ...

Report | 04-03-2019

Patiromer (Veltassa®) for the treatment of hyperkalaemia in adults

Zorginstituut Nederland has carried out an assessment whether patiromer (Veltassa®) is interchangeable with a medicinal product ...

Report | 25-02-2019

Tisagenlecleucel-T (Kymriah®) for the treatment of ALL

Zorginstituut Nederland carried out an assessment of the medicinal product tisagenlecleucel-T (Kymriah®) for the treatment of ...

Report | 18-12-2018

Lesinurad (Zurampic®) for the treatment of hyperuricaemia in gout patients

Zorginstituut Nederland carried out an assessment whether lesinurad (Zurampic®) is interchangeable with any product that is ...

Report | 04-12-2018